FABRAZYME

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug FABRAZYME contains one active pharmaceutical ingredient (API):

1 Agalsidase beta
UNII RZD65TSM9U - AGALSIDASE BETA

Agalsidase beta is a recombinant form of human α-galactosidase A and is produced by recombinant DNA technology using a mammalian Chinese Hamster Ovary (CHO) cell culture. The amino acid sequence of the recombinant form, as well as the nucleotide sequence which encoded it, are identical to the natural form of α-galactosidase.

Read about Agalsidase beta

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
FABRAZYME Powder for concentrate solution European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
A16AB04 Agalsidase beta A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 576720020056117
Country: CA Health Products and Food Branch Identifier(s): 02248965, 02248966
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 133-MBE-0319, 8-MBE-0514
Country: EE Ravimiamet Identifier(s): 1127359, 1127663, 1209732, 1209743, 1209765, 1209776
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 01188001, 01188004
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 006732, 016930
Country: FR Base de données publique des médicaments Identifier(s): 64569676
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 95244, 95247
Country: HK Department of Health Drug Office Identifier(s): 55821, 55822
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 6737
Country: JP 医薬品医療機器総合機構 Identifier(s): 3959409D1029, 3959409D2025
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1028369, 1028370, 1028371, 1028392, 1028393, 1028394
Country: NL Z-Index G-Standaard Identifier(s): 14695898, 14889110
Country: NL Z-Index G-Standaard, PRK Identifier(s): 60518, 70254
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100111357, 100212727
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W08961001, W08961002, W08961003, W52556001, W52556002, W52556003
Country: SG Health Sciences Authority Identifier(s): 13609P, 13610P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 3843041H
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699809260054
Country: US FDA, National Drug Code Identifier(s): 58468-0040, 58468-0041
Country: ZA Health Products Regulatory Authority Identifier(s): 46/31/0583, 46/31/0584

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.